Stryker Co. (NYSE:SYK) is HealthInvest Partners AB’s 7th Largest Position

HealthInvest Partners AB grew its position in shares of Stryker Co. (NYSE:SYK) by 9.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 25,660 shares of the medical technology company’s stock after acquiring an additional 2,200 shares during the period. Stryker comprises about 4.3% of HealthInvest Partners AB’s holdings, making the stock its 7th largest holding. HealthInvest Partners AB’s holdings in Stryker were worth $9,296,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SYK. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the 4th quarter worth about $30,000. Darwin Wealth Management LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $36,000. Activest Wealth Management purchased a new stake in Stryker during the 4th quarter valued at $36,000. Finally, Crews Bank & Trust bought a new position in shares of Stryker during the 4th quarter valued at $39,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SYK. Argus set a $450.00 price objective on Stryker in a report on Monday, February 3rd. Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. UBS Group upped their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $422.15.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 1.0 %

Shares of SYK opened at $382.59 on Monday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $145.99 billion, a PE ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The business’s 50 day moving average is $378.07 and its 200 day moving average is $369.34.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm earned $3.46 EPS. Research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s payout ratio is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.